Hossein-Ardeschir Ghofrani
Overview
Explore the profile of Hossein-Ardeschir Ghofrani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
5546
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hoeper M, Oerke B, Wissmuller M, Leuchte H, Opitz C, Halank M, et al.
Circulation
. 2024 Jun;
150(8):600-610.
PMID: 38939948
Background: We assessed the efficacy and safety of tadalafil, a phosphodiesterase type 5 inhibitor, in patients with heart failure with preserved ejection fraction and combined postcapillary and precapillary pulmonary hypertension....
12.
Benza R, Simonneau G, Ghofrani H, Corris P, Langleben D, Rosenkranz S, et al.
J Heart Lung Transplant
. 2024 Jun;
43(10):1756-1760.
PMID: 38852934
In Riociguat rEplacing PDE5i therapy evaLuated Against Continued PDE5i thErapy (REPLACE) (NCT02891850), improvements in risk status were observed in patients with pulmonary arterial hypertension (PAH) at intermediate risk switching to...
13.
Schlueter B, Quanz K, Baldauf J, Petrovic A, Ruppert C, Guenther A, et al.
Vascul Pharmacol
. 2024 May;
155:107379.
PMID: 38762131
Pulmonary hypertension (PH) is a progressive, severe and to date not curable disease of the pulmonary vasculature. Alterations of the insulin-like growth factor 1 (IGF-1) system are known to play...
14.
Frantz R, McLaughlin V, Sahay S, Escribano Subias P, Zolty R, Benza R, et al.
Lancet Respir Med
. 2024 May;
12(7):523-534.
PMID: 38705167
Background: Morbidity and mortality in pulmonary arterial hypertension (PAH) remain high. Activation of platelet-derived growth factor receptor, colony stimulating factor 1 receptor, and mast or stem cell growth factor receptor...
15.
Ghofrani H, Simonneau G, DArmini A, Fedullo P, Howard L, Jais X, et al.
Lancet Respir Med
. 2024 Mar;
12(4):e21-e30.
PMID: 38548406
Background: Macitentan is beneficial for long-term treatment of pulmonary arterial hypertension. The microvasculopathy of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension are similar. Methods: The phase 2, double-blind,...
16.
Gomberg-Maitland M, McLaughlin V, Badesch D, Ghofrani H, Hoeper M, Humbert M, et al.
JACC Heart Fail
. 2023 Jul;
11(10):1457-1459.
PMID: 37452806
No abstract available.
17.
Humbert M, McLaughlin V, Gibbs J, Gomberg-Maitland M, Hoeper M, Preston I, et al.
Eur Respir J
. 2022 Aug;
61(1).
PMID: 36041750
Background: In participants with pulmonary arterial hypertension, 24 weeks of sotatercept resulted in a significantly greater reduction from baseline in pulmonary vascular resistance than placebo. This report characterises the longer-term...
18.
Majeed R, Wilkins M, Howard L, Hassoun P, Anthi A, Cajigas H, et al.
Pulm Circ
. 2022 Aug;
12(3):e12123.
PMID: 36034404
The Pulmonary Vascular Research Institute GoDeep meta-registry is a collaboration of pulmonary hypertension (PH) reference centers across the globe. Merging worldwide PH data in a central meta-registry to allow advanced...
19.
Ghofrani H, Kim N
Lancet Respir Med
. 2022 Aug;
10(10):926-927.
PMID: 35926545
No abstract available.
20.